# Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).

> **NCT02026362** · PHASE1,PHASE2 · SUSPENDED · sponsor: **HRYZ Biotech Co.** · enrollment: 100 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** MASCT:Multiple Antigens Specific Cellular Therapy
- **OTHER:** The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment

## Key facts

- **NCT ID:** NCT02026362
- **Lead sponsor:** HRYZ Biotech Co.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2013-07
- **Primary completion:** 2017-07
- **Final completion:** 2019-12
- **Target enrollment:** 100 (ESTIMATED)
- **Why stopped:** Interim analysis
- **Last updated:** 2017-10-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02026362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02026362, "Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02026362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*